Terms: = Lymphoma AND TNFRSF17, BCMA, 608, ENSG00000048462, CD269, Q02223, BCM AND Prognosis
19 results:
1. Hepatitis B surface antigen positivity is associated with poor short- and long-term outcomes in patients with diffuse large B-cell lymphoma who received CHOP or R-CHOP.
Zhan Z; Guo W; Wan X; Wang B; Li J; Wang H; Li Z; Huang Y; Young KH; Bai O
Front Immunol; 2024; 15():1324113. PubMed ID: 38318173
[TBL] [Abstract] [Full Text] [Related]
2. Broadening the horizon: potential applications of CAR-T cells beyond current indications.
Karsten H; Matrisch L; Cichutek S; Fiedler W; Alsdorf W; Block A
Front Immunol; 2023; 14():1285406. PubMed ID: 38090582
[TBL] [Abstract] [Full Text] [Related]
3. [Clinical analysis of long-term survival and influencing factors of chimeric antigen receptor T-cell therapy in relapsed/refractory acute B-cell lymphoblastic leukemia].
Wang Y; Gao QY; Wang H; Zhang D; Gao Y; Miao YD; Zhai XH; Hu XX; Rui XL; Zhang WH
Zhonghua Xue Ye Xue Za Zhi; 2023 Oct; 44(10):800-804. PubMed ID: 38049330
[No Abstract] [Full Text] [Related]
4. Long non-coding RNA as a novel biomarker and therapeutic target in aggressive B-cell non-Hodgkin lymphoma: A systematic review.
Khanmohammadi S; Fallahtafti P
J Cell Mol Med; 2023 Jul; 27(14):1928-1946. PubMed ID: 37246627
[TBL] [Abstract] [Full Text] [Related]
5. bcma CAR-T induces complete and durable remission in refractory plasmablastic lymphoma.
Raghunandan S; Pauly M; Blum WG; Qayed M; Dhodapkar MV; Elkhalifa M; Watkins B; Schoettler M; Horwitz E; Parikh S; Chandrakasan S; Leung K; Bryson E; Deeb L; Kaufman JL; Worthington-White D; Alazraki A; Schecter JM; Madduri D; Jackson CC; Zudaire E; Taraseviciute-Morris A; Babich A; Nesheiwat T; Vogel M; Lendvai N; Pacaud L; Williams KM
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37137553
[TBL] [Abstract] [Full Text] [Related]
6. Heterogeneity of B cell lymphopoiesis in patients with premalignant and active myeloma.
Jakubikova J; Cholujova D; Beke G; Hideshima T; Klucar L; Leiba M; Jamroziak K; Richardson PG; Kastritis E; Dorfman DM; Anderson KC
JCI Insight; 2023 Feb; 8(3):. PubMed ID: 36752202
[TBL] [Abstract] [Full Text] [Related]
7. GATA3 Expression in Human Tumors: A Tissue Microarray Study on 16,557 Tumors.
Reiswich V; Schmidt CE; Lennartz M; Höflmayer D; Hube-Magg C; Weidemann S; Fraune C; Büscheck F; Möller K; Bernreuther C; Simon R; Clauditz TS; Blessin NC; Bady E; Sauter G; Uhlig R; Steurer S; Minner S; Burandt E; Dum D; Marx AH; Krech T; Lebok P; Hinsch A; Jacobsen F
Pathobiology; 2023; 90(4):219-232. PubMed ID: 36649695
[TBL] [Abstract] [Full Text] [Related]
8. The role of soluble B cell maturation antigen as a biomarker in multiple myeloma.
Alomari M; Kunacheewa C; Manasanch EE
Leuk Lymphoma; 2023 Feb; 64(2):261-272. PubMed ID: 36282671
[TBL] [Abstract] [Full Text] [Related]
9. Belantamab in Combination with Dexamethasone in Patients with Triple-class Relapsed/Refractory Multiple Myeloma.
Atieh T; Atrash S; Ahmed N; Mohan M; Cui W; Shune L; Hajjar S; Mahmoudjafari Z; Quick J; Wishna A; Riffel J; McGuirk J; Mohyuddin GR; Abdallah AO
Clin Lymphoma Myeloma Leuk; 2022 Dec; 22(12):912-919. PubMed ID: 36127271
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical Significance of Tfh/Tfr Cell Imbalance in Patients with B-Cell lymphoma].
Zheng J; Zhang Z; Chen YH; Xiao Y; Shen R; Wang L; Zhang P; Yang QY; Feng C; Gao KB
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Oct; 29(5):1510-1516. PubMed ID: 34627432
[TBL] [Abstract] [Full Text] [Related]
11. Emerging Targets and Cellular Therapy for Relapsed Refractory Multiple Myeloma: A Systematic Review.
George LL; Deshpande SR; Cortese MJ; Kendall EK; Chattaraj A; Shah Z; Zhao J; Anwer F
Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):741-751. PubMed ID: 34253497
[TBL] [Abstract] [Full Text] [Related]
12. [Semiquantitative parameters of
Liao XH; Wang RF; Liu M; Chen XQ; Xiong Y; Nong L; Yin L; Zhang BY; DU YJ
Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Oct; 53(2):246-254. PubMed ID: 33879893
[TBL] [Abstract] [Full Text] [Related]
13. Overcoming Chimeric Antigen Receptor (CAR) Modified T-Cell Therapy Limitations in Multiple Myeloma.
García-Guerrero E; Sierro-Martínez B; Pérez-Simón JA
Front Immunol; 2020; 11():1128. PubMed ID: 32582204
[TBL] [Abstract] [Full Text] [Related]
14. Improved Outcomes of All-trans-retinoic Acid and Arsenic Trioxide Plus Idarubicin as a Frontline Treatment in Adult Patients With Acute Promyelocytic Leukemia.
Yang S; Ma R; Yuan X; Jiang L; Shi J; Yang J; Lei P; Zang Y; Chen X; Zhang Y; Liu Z; Guo J; Zhang L; Zhu X; Zhu Z
Clin Lymphoma Myeloma Leuk; 2020 Jul; 20(7):e382-e391. PubMed ID: 32336675
[TBL] [Abstract] [Full Text] [Related]
15. Case report: simultaneous occurrence of multiple myeloma and non-Hodgkin lymphoma treated by CAR T therapy.
Li T; Tan J; Chen L; Kuang D; Mao X; Lou Y; Zhou J; Zhou X
Medicine (Baltimore); 2020 Apr; 99(16):e19739. PubMed ID: 32311967
[TBL] [Abstract] [Full Text] [Related]
16. [Prognostic significance of NCCN-International Prognostic Index (NCCN-IPI) for patients with peripheral T-cell lymphoma treated with CHOP-based chemotherapy].
Zhang MC; Xu PP; Zhong HJ; Zhao X; Zhao WL; Cheng S
Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):772-777. PubMed ID: 29081194
[No Abstract] [Full Text] [Related]
17. [Children's NK/T Cell lymphoma-Associated Hemophagocytic Syndrome: Clinical Analysis of 6 Cases].
Zheng YZ; Zheng H; Li J; LE SH; Hua XL; Chen ZS; Zheng L; Li M; Chen YQ; Gao QL; Yang JH; Hu JD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Dec; 24(6):1764-1770. PubMed ID: 28024491
[TBL] [Abstract] [Full Text] [Related]
18. Association between genetic variations in tumor necrosis factor receptor genes and survival of patients with T-cell lymphoma.
Zhai K; Chang J; Wu C; Lu N; Huang LM; Zhang TW; Yu DK; Tan W; Lin DX
Chin J Cancer; 2012 Jul; 31(7):335-41. PubMed ID: 22640629
[TBL] [Abstract] [Full Text] [Related]
19. APRIL is overexpressed in cancer: link with tumor progression.
Moreaux J; Veyrune JL; De Vos J; Klein B
BMC Cancer; 2009 Mar; 9():83. PubMed ID: 19291294
[TBL] [Abstract] [Full Text] [Related]
